As MDM2 expression has been associated with poor prognosis GISTSs (48) and MDM2 inhibitors (33) demonstrated to suppress growth and induced apoptosis in WT p53 GIST cells, the use of MDM2 inhibitors may be an additional strategy beyond KIT and PDGFRA in future studies. Here, MDM2 is linked to gastrointestinal stromal tumor.